Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nov 25, 2022 05:29 am
DUBLIN -- 

The "Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The assessment part of the report embraces, in depth Chronic Hepatitis Delta Virus (HDV) Infection commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis Delta Virus (HDV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis Delta Virus (HDV) Infection.

Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Chapters

This segment of the Chronic Hepatitis Delta Virus (HDV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs

Lonafarnib: Eiger Biopharmaceuticals

Eiger's lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.

JNJ-73763989: Janssen Pharmaceuticals

Janssen "breakthrough" drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral class molecule designed to treat HVB and HVD infection via RNA interference mechanism. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.

Chronic Hepatitis Delta Virus (HDV) Infection: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Hepatitis Delta Virus (HDV) Infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Hepatitis Delta Virus (HDV) Infection

There are approx. 10+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III include, Eiger Biopharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Chronic Hepatitis Delta Virus (HDV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Hepatitis Delta Virus (HDV) Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis Delta Virus (HDV) Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis Delta Virus (HDV) Infection drugs.

Chronic Hepatitis Delta Virus (HDV) Infection Report Insights

  • Chronic Hepatitis Delta Virus (HDV) Infection Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Chronic Hepatitis Delta Virus (HDV) Infection Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Players

  • Janssen Pharmaceuticals
  • Eiger Biopharmaceutical
  • Pharma Essentia
  • Vir Biotechnology, Inc.
  • Huahui Health
  • Antios Therapeutics

Key Products

  • JNJ-73763989
  • Lonafarinib
  • P1101
  • VIR 2218
  • VIR 3434
  • Nivolumab
  • HH 003
  • ATI 2173

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/wr0q5q

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).